ES2639625T3 - Composiciones para prevenir adherencias y otras aplicaciones de barrera - Google Patents
Composiciones para prevenir adherencias y otras aplicaciones de barrera Download PDFInfo
- Publication number
- ES2639625T3 ES2639625T3 ES12196176.7T ES12196176T ES2639625T3 ES 2639625 T3 ES2639625 T3 ES 2639625T3 ES 12196176 T ES12196176 T ES 12196176T ES 2639625 T3 ES2639625 T3 ES 2639625T3
- Authority
- ES
- Spain
- Prior art keywords
- self
- xaa
- peptides
- xaaneu
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 230000004888 barrier function Effects 0.000 title claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 234
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 185
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 18
- 238000001356 surgical procedure Methods 0.000 claims abstract description 18
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 17
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 13
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 13
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 13
- 230000006378 damage Effects 0.000 claims abstract description 10
- 208000014674 injury Diseases 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 9
- 210000001124 body fluid Anatomy 0.000 claims abstract description 8
- 239000010839 body fluid Substances 0.000 claims abstract description 8
- 230000007935 neutral effect Effects 0.000 claims abstract description 6
- 210000001519 tissue Anatomy 0.000 claims description 40
- 150000002500 ions Chemical class 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 12
- 210000000936 intestine Anatomy 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 241001269524 Dura Species 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000004051 gastric juice Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003973 paint Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000003872 anastomosis Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000001613 integumentary system Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000001819 pancreatic juice Anatomy 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000004915 pus Anatomy 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 32
- 239000000463 material Substances 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 28
- 230000002209 hydrophobic effect Effects 0.000 description 28
- 238000001338 self-assembly Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- 238000009472 formulation Methods 0.000 description 15
- 239000007787 solid Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000004962 physiological condition Effects 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 230000007704 transition Effects 0.000 description 10
- -1 anti-infectives Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 231100000241 scar Toxicity 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004365 Protease Substances 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 125000002355 alkine group Chemical group 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000008241 heterogeneous mixture Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- XBPKRVHTESHFAA-LURJTMIESA-N (2s)-2-azaniumyl-2-cyclopentylacetate Chemical compound OC(=O)[C@@H](N)C1CCCC1 XBPKRVHTESHFAA-LURJTMIESA-N 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000002009 alkene group Chemical group 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229920001002 functional polymer Polymers 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
- HNYAWMSQSBERBE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hexanoate Chemical compound CCCCCC(=O)ON1C(=O)CCC1=O HNYAWMSQSBERBE-UHFFFAOYSA-N 0.000 description 1
- NTEDOEBWPRVVSG-FQUUOJAGSA-N (2s)-1-[(2r)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CO)C(=O)N1CCC[C@H]1C(O)=O NTEDOEBWPRVVSG-FQUUOJAGSA-N 0.000 description 1
- AGOOUZZBQZNYCU-AJNGGQMLSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(O)=O AGOOUZZBQZNYCU-AJNGGQMLSA-N 0.000 description 1
- CWAHAVYVGPRZJU-XUXIUFHCSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CWAHAVYVGPRZJU-XUXIUFHCSA-N 0.000 description 1
- MDNRBNZIOBQHHK-KWBADKCTSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N MDNRBNZIOBQHHK-KWBADKCTSA-N 0.000 description 1
- ZRVZOBGMZWVJOS-VMXHOPILSA-N (2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN ZRVZOBGMZWVJOS-VMXHOPILSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- RGNVSYKVCGAEHK-GUBZILKMSA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O RGNVSYKVCGAEHK-GUBZILKMSA-N 0.000 description 1
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- GERXSZLDSOPHJV-UHFFFAOYSA-N (4-nitrophenyl) 2-iodoacetate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)CI)C=C1 GERXSZLDSOPHJV-UHFFFAOYSA-N 0.000 description 1
- MYBITMLLBJNNSS-UHFFFAOYSA-N 1-(cyclohexanecarbonyloxy)-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound OS(=O)(=O)C1CC(=O)N(OC(=O)C2CCCCC2)C1=O MYBITMLLBJNNSS-UHFFFAOYSA-N 0.000 description 1
- UMZVBZDHGKJFGQ-UHFFFAOYSA-N 1-[2-[[2-[[2-[[2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCCC(NC(=O)CN)C(=O)NCC(=O)NC(CC(O)=O)C(=O)NC(C(O)C)C(=O)N1CCCC1C(O)=O UMZVBZDHGKJFGQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010056519 Abdominal infection Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- AGPKZVBTJJNPAG-CRCLSJGQSA-N D-allo-isoleucine Chemical compound CC[C@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-CRCLSJGQSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000021559 Dicerandra Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102100039250 Essential MCU regulator, mitochondrial Human genes 0.000 description 1
- 108010018907 Gly-Arg-Gly-Asp-Ser-Pro-Cys Proteins 0.000 description 1
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000813097 Homo sapiens Essential MCU regulator, mitochondrial Proteins 0.000 description 1
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 108010067520 RADA16-I Proteins 0.000 description 1
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 1
- 241000702660 Rice gall dwarf virus Species 0.000 description 1
- 206010041101 Small intestinal obstruction Diseases 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 108010000421 fibronectin attachment peptide Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010064365 glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine Proteins 0.000 description 1
- 108010084991 glycyl-alanyl-valyl-seryl-threonyl-alanine Proteins 0.000 description 1
- 108010084136 glycyl-arginyl-alanyl-aspartyl-seryl-proline Proteins 0.000 description 1
- 108010088970 glycyl-arginyl-glycyl-aspartyl-asparaginyl-proline Proteins 0.000 description 1
- 108010034892 glycyl-arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- 108010053299 glycyl-arginyl-glycyl-aspartyl-seryl-proline Proteins 0.000 description 1
- 108010013726 glycyl-arginyl-glycyl-glutamyl-serine Proteins 0.000 description 1
- 108010044896 glycyl-arginyl-glycyl-glutamyl-seryl-proline Proteins 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- ZMJGSOSNSPKHNH-UHFFFAOYSA-N pyridoxamine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN)=C1O ZMJGSOSNSPKHNH-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/740,284 US9162005B2 (en) | 2005-04-25 | 2007-04-25 | Compositions for prevention of adhesions and other barrier applications |
| US740284 | 2007-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2639625T3 true ES2639625T3 (es) | 2017-10-27 |
Family
ID=39620203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12196176.7T Active ES2639625T3 (es) | 2007-04-25 | 2008-04-25 | Composiciones para prevenir adherencias y otras aplicaciones de barrera |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9162005B2 (enExample) |
| EP (2) | EP2581097B1 (enExample) |
| JP (3) | JP5976272B2 (enExample) |
| CA (1) | CA2722465C (enExample) |
| DK (1) | DK2581097T3 (enExample) |
| ES (1) | ES2639625T3 (enExample) |
| HU (1) | HUE034194T2 (enExample) |
| PL (1) | PL2581097T3 (enExample) |
| WO (1) | WO2008134544A1 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4023240A1 (en) * | 2004-07-06 | 2022-07-06 | 3D Matrix, Inc. | Purified amphiphilic peptide compositions and uses thereof |
| US9327010B2 (en) | 2005-04-25 | 2016-05-03 | Massachusetts Institute Of Technology | Compositions and methods for promoting hemostasis and other physiological activities |
| US9162005B2 (en) | 2005-04-25 | 2015-10-20 | Arch Biosurgery, Inc. | Compositions for prevention of adhesions and other barrier applications |
| US9877921B2 (en) * | 2005-09-09 | 2018-01-30 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| US20160045457A1 (en) | 2005-09-09 | 2016-02-18 | Ousama Rachid | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| CN101472620A (zh) | 2006-04-25 | 2009-07-01 | 麻省理工学院 | 用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法 |
| DK2146733T3 (da) * | 2007-03-14 | 2021-01-11 | Arch Biosurgery Inc | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |
| US7906478B2 (en) * | 2007-07-20 | 2011-03-15 | The Procter & Gamble Company | Personal-care articles having self-assembling peptides |
| WO2009067711A2 (en) | 2007-11-21 | 2009-05-28 | T.J. Smith & Nephew, Limited | Suction device and dressing |
| GB0722820D0 (en) | 2007-11-21 | 2008-01-02 | Smith & Nephew | Vacuum assisted wound dressing |
| EP3354243A1 (en) | 2007-11-21 | 2018-08-01 | Smith & Nephew PLC | Wound dressing |
| EP2229960B1 (en) * | 2007-12-05 | 2015-04-08 | 3-D Matrix, Ltd. | Wound healing/skin reconstruction material |
| US20130096518A1 (en) | 2007-12-06 | 2013-04-18 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| US11253399B2 (en) | 2007-12-06 | 2022-02-22 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| GB0723875D0 (en) | 2007-12-06 | 2008-01-16 | Smith & Nephew | Wound management |
| GB0803564D0 (en) | 2008-02-27 | 2008-04-02 | Smith & Nephew | Fluid collection |
| GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
| US9023376B2 (en) * | 2008-06-27 | 2015-05-05 | The University Of Akron | Nanofiber-reinforced composition for application to surgical wounds |
| GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
| EP2345433B1 (en) * | 2008-10-06 | 2017-03-01 | 3-D Matrix, Ltd. | Tissue plug |
| GB0902816D0 (en) | 2009-02-19 | 2009-04-08 | Smith & Nephew | Fluid communication path |
| US9439941B2 (en) | 2009-12-14 | 2016-09-13 | The University Of Hong Kong | Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells |
| US20120322884A1 (en) | 2010-03-01 | 2012-12-20 | University Of Manitoba | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| US9061095B2 (en) | 2010-04-27 | 2015-06-23 | Smith & Nephew Plc | Wound dressing and method of use |
| GB201011173D0 (en) | 2010-07-02 | 2010-08-18 | Smith & Nephew | Provision of wound filler |
| US20130281602A1 (en) * | 2010-10-08 | 2013-10-24 | Solvay Sa | Thermo-responsive polymer covalently bound with a peptide |
| BR112013012785A2 (pt) | 2010-11-25 | 2020-10-20 | Bluestar Silicones France Sas | composição i - ii e produtos e usos das mesmas |
| GB201020005D0 (en) | 2010-11-25 | 2011-01-12 | Smith & Nephew | Composition 1-1 |
| GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
| US8546338B2 (en) | 2010-12-08 | 2013-10-01 | Johnson & Johnson Consumer Companies, Inc. | Self-assembling hydrogels based on dicephalic peptide amphiphiles |
| EP2648794B1 (en) | 2010-12-08 | 2019-08-28 | ConvaTec Technologies Inc. | Wound exudate system accessory |
| US10207031B2 (en) | 2010-12-08 | 2019-02-19 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
| DK2648795T3 (da) | 2010-12-08 | 2023-03-27 | Convatec Technologies Inc | System til fjernelse af eksudater fra en sårposition |
| GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
| EP2753321B1 (en) * | 2011-10-21 | 2021-12-15 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| US9243037B2 (en) | 2011-11-10 | 2016-01-26 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
| US20150159066A1 (en) | 2011-11-25 | 2015-06-11 | Smith & Nephew Plc | Composition, apparatus, kit and method and uses thereof |
| GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
| GB201120693D0 (en) | 2011-12-01 | 2012-01-11 | Convatec Technologies Inc | Wound dressing for use in vacuum therapy |
| KR101345333B1 (ko) * | 2011-12-30 | 2013-12-30 | 조선대학교산학협력단 | 라이신 및 트립토판 잔기가 ４번 반복된 신규한 항균 및 항진균 펩타이드 및 이의 용도 |
| CA2876883C (en) | 2012-06-15 | 2022-11-01 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| JP6389170B2 (ja) | 2012-07-06 | 2018-09-12 | スリーディー マトリックス， エルティーディー３−Ｄ Ｍａｔｒｉｘ， Ｌｔｄ． | ペプチド溶液のためのフィル−フィニッシュ過程 |
| WO2014012165A1 (en) | 2012-07-19 | 2014-01-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| ES2933048T3 (es) | 2012-08-17 | 2023-01-31 | Amsilk Gmbh | Uso de polipéptidos de autoensamblaje como adhesivos tisulares |
| JP2016507663A (ja) | 2012-12-20 | 2016-03-10 | コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ | 化学修飾セルロース系繊維の加工 |
| KR20160003651A (ko) * | 2013-03-14 | 2016-01-11 | 가부시끼가이샤 쓰리디 매트릭스 | 위장 폐색 예방용 물질 |
| EP2968647B1 (en) | 2013-03-15 | 2022-06-29 | Smith & Nephew plc | Wound dressing sealant and use thereof |
| US20160120706A1 (en) | 2013-03-15 | 2016-05-05 | Smith & Nephew Plc | Wound dressing sealant and use thereof |
| HRP20211286T1 (hr) | 2013-03-22 | 2021-12-24 | Nova Southeastern University | Fine čestice epinefrina i metode njihove korištenja za liječenje stanja koja odgovaraju na epinefrin |
| DE102013211316A1 (de) * | 2013-06-17 | 2014-12-18 | Aesculap Ag | Hämostyptikum |
| CN105658252A (zh) | 2013-08-22 | 2016-06-08 | 阿奇生物外科有限公司 | 用于控制流体移动的可植入网状物 |
| CA2939696C (en) | 2014-03-10 | 2023-01-10 | 3-D Matrix, Ltd. | Self-assembling peptide compositions |
| ES2712608T3 (es) | 2014-03-10 | 2019-05-14 | 3 D Matrix Ltd | Péptidos autoensamblantes para el tratamiento de las bullas pulmonares |
| JP6684719B2 (ja) | 2014-03-10 | 2020-04-22 | 株式会社スリー・ディー・マトリックス | ペプチド組成物の滅菌および濾過 |
| GB2543544A (en) | 2015-10-21 | 2017-04-26 | Brightwake Ltd | Wound dressing |
| WO2017106460A1 (en) * | 2015-12-15 | 2017-06-22 | 3-D Matrix, Ltd. | Self-assembling peptides comprising non-ionic polar amino acids for anti-adhesion |
| WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
| US20190091376A1 (en) * | 2016-03-18 | 2019-03-28 | 3-D Matrix, Ltd. | Preventing Biological Tissue Adhesion |
| US20210023257A1 (en) * | 2016-03-18 | 2021-01-28 | 3-D Matrix, Ltd. | Cerebrospinal fluid leakage occlusion |
| WO2017173069A1 (en) | 2016-03-30 | 2017-10-05 | Convatec Technologies Inc. | Detecting microbial infections in wounds |
| KR20190008199A (ko) | 2016-03-30 | 2019-01-23 | 시노보 게엠베하 | 상처에서 미생물 감염의 검출 방법 |
| GB201608099D0 (en) | 2016-05-09 | 2016-06-22 | Convatec Technologies Inc | Negative pressure wound dressing |
| WO2018005427A1 (en) * | 2016-06-27 | 2018-01-04 | 3-D Matrix, Ltd. | Self-assembling peptide matrix for the prevention of esophageal stricture after endoscopic dissection |
| BR112019000284A2 (pt) | 2016-07-08 | 2019-04-16 | Convatec Technologies Inc. | aparelho de coleta de fluido |
| MX2019000232A (es) | 2016-07-08 | 2019-11-12 | Convatec Technologies Inc | Deteccion de flujo de fluidos. |
| CA3030152A1 (en) | 2016-07-08 | 2018-01-11 | Convatec Technologies Inc. | Flexible negative pressure system |
| WO2019089856A1 (en) | 2017-10-31 | 2019-05-09 | InMEDBio, LLC | Absorbent, breathable and pathogen blocking/killing wound care dressing and fabrication thereof |
| EP3710074B1 (en) | 2017-11-16 | 2024-03-20 | ConvaTec Limited | Fluid collection apparatus |
| EP3723726A1 (en) | 2017-12-15 | 2020-10-21 | 3-D Matrix, Ltd. | Surfactant peptide nanostructures and uses in drug delivery |
| CA3094984A1 (en) | 2018-03-23 | 2019-09-26 | Arch Biosurgery, Inc. | Sap and peptidomimetic compositions for reducing symptoms of inflammation |
| EP3768296B1 (en) | 2018-03-23 | 2023-09-06 | Arch Biosurgery, Inc. | Sap and peptidomimetics for treatment of eye disease |
| WO2020071527A1 (ja) * | 2018-10-05 | 2020-04-09 | 学校法人 久留米大学 | 腸管における潰瘍または瘻孔の治療または予防のための医薬組成物 |
| CA3116730A1 (en) | 2018-10-19 | 2020-04-23 | Nova Southeastern University | Sublingual epinephrine compositions including ph-modifying excipients and penetration enhancers and methods for use thereof |
| CN109513044B (zh) * | 2019-01-29 | 2022-02-18 | 北京颢美细胞基因生物技术有限公司 | 用于微整形的再生组织基质微粒植入剂、制备方法及应用 |
| JP7372316B2 (ja) * | 2019-04-09 | 2023-10-31 | 富士フイルム株式会社 | 内視鏡用架橋体、内視鏡、及び内視鏡用架橋体を形成するための組成物 |
| WO2020245656A1 (en) | 2019-06-03 | 2020-12-10 | Convatec Limited | Methods and devices to disrupt and contain pathogens |
| US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
| US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
| EP4090350A1 (en) * | 2020-01-13 | 2022-11-23 | Arch Biosurgery, Inc. | Self-assembling peptide gel formulation and methods of use |
| WO2023108026A2 (en) * | 2021-12-08 | 2023-06-15 | Oakgrove Bio Llc | Biological production of histidine-rich peptides |
| EP4635970A1 (en) * | 2022-12-16 | 2025-10-22 | Toagosei Co., Ltd. | Synthetic peptide and construct |
| CN116789854B (zh) * | 2023-06-08 | 2024-04-02 | 东北农业大学 | 兼具细菌捕获与抑菌功能的纳米抗菌肽及制备方法和应用 |
| CN118978602B (zh) * | 2024-07-29 | 2025-06-10 | 东北农业大学 | 一种具有免疫调节功能的pH响应型纳米抗菌肽及其制备方法和应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4098728A (en) * | 1976-01-02 | 1978-07-04 | Solomon Rosenblatt | Medical surgical sponge and method of making same |
| US4211227A (en) * | 1978-07-03 | 1980-07-08 | The Kendall Company | Surgical sponge material |
| US4272398A (en) * | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
| US4636208A (en) * | 1984-10-05 | 1987-01-13 | Ewald Rath | Surgical sponge |
| US4829000A (en) | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
| US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
| US5019646A (en) | 1987-08-25 | 1991-05-28 | Regents Of The University Of Minnesota | Polypeptides with fibronectin activity |
| US5843156A (en) | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
| JP2528602B2 (ja) * | 1989-12-04 | 1996-08-28 | ケンゼー・ナッシュ・コーポレーション | 開口部を封止するためのプラグ装置 |
| US5180375A (en) * | 1991-05-02 | 1993-01-19 | Feibus Miriam H | Woven surgical drain and woven surgical sponge |
| US5222974A (en) * | 1991-11-08 | 1993-06-29 | Kensey Nash Corporation | Hemostatic puncture closure system and method of use |
| US5955343A (en) * | 1992-12-28 | 1999-09-21 | Massachusetts Institute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| US5670483A (en) * | 1992-12-28 | 1997-09-23 | Massachusetts Insititute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| US5645565A (en) * | 1995-06-13 | 1997-07-08 | Ethicon Endo-Surgery, Inc. | Surgical plug |
| US5762846A (en) | 1996-12-20 | 1998-06-09 | E. I. Du Pont De Nemours And Company | Dispersion spinning process for polytetrafluoroethylene and related polymers |
| US6368877B1 (en) * | 1997-06-25 | 2002-04-09 | Massachusetts Institute Of Technology | Self-assembling peptide surfaces for cell patterning and interactions |
| US5956343A (en) | 1997-12-23 | 1999-09-21 | Alcatel Usa Sourcing L.P. | Designating a control channel in a telecommunications system |
| US6235340B1 (en) | 1998-04-10 | 2001-05-22 | Massachusetts Institute Of Technology | Biopolymer-resistant coatings |
| WO2000041732A1 (en) * | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
| WO2000063079A1 (en) * | 1999-04-15 | 2000-10-26 | Ultracell Medical Technologies Of Connecticut, Inc. | Method for producing surgical sponge device and product thereof |
| US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
| US6953659B2 (en) * | 2000-07-14 | 2005-10-11 | Massachusetts Institute Of Technology | Direct, externally imposed control of nucleic acids |
| US6953656B2 (en) | 2000-07-14 | 2005-10-11 | Massachusetts Institute Of Technology | Direct, externally imposed control of polypeptides |
| US6846319B2 (en) * | 2000-12-14 | 2005-01-25 | Core Medical, Inc. | Devices for sealing openings through tissue and apparatus and methods for delivering them |
| DE60232308D1 (de) * | 2001-01-31 | 2009-06-25 | Asahi Glass Co Ltd | Verfahren zur herstellung von fluorinverbindungen |
| ATE419333T1 (de) | 2001-02-06 | 2009-01-15 | Massachusetts Inst Technology | Peptidgerüstverkapselung von gewebszellen und verwendungen davon |
| US7449180B2 (en) * | 2001-02-06 | 2008-11-11 | John Kisiday | Macroscopic scaffold containing amphiphilic peptides encapsulating cells |
| EP1402001A4 (en) * | 2001-05-04 | 2006-05-24 | Scripps Research Inst | ANTIMICROBIAL PEPTIDES AND COMPOSITIONS |
| WO2003006043A1 (en) * | 2001-07-10 | 2003-01-23 | Massachusetts Institute Of Technology | Surfactant peptide nanostructures, and uses thereof |
| WO2003052117A2 (en) * | 2001-09-19 | 2003-06-26 | Massachusetts Institute Of Technology | Methods and products related to non-viral transfection |
| WO2003084980A2 (en) | 2002-04-02 | 2003-10-16 | Northwestern University | Peptide amphiphile solutions and self assembled peptide nanofiber networks |
| WO2003096972A2 (en) | 2002-05-13 | 2003-11-27 | Massachusetts Institute Of Technology | Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof |
| CA2387257C (en) * | 2002-05-23 | 2009-07-28 | Suncor Energy Inc. | Static deaeration conditioner for processing of bitumen froth |
| GB0216286D0 (en) | 2002-07-15 | 2002-08-21 | Univ Leeds | Network |
| JP2005534697A (ja) * | 2002-08-06 | 2005-11-17 | エピックス ファーマシューティカルズ， インコーポレイテッド | ペプチド凝集体 |
| MXPA05008483A (es) | 2003-02-11 | 2006-03-10 | Univ Northwestern | Metodos y materiales para revestimientos de superficie nanocristalinos y union de nanofibras de anfililos peptidicos sobre las mismas. |
| WO2004110964A2 (en) * | 2003-06-16 | 2004-12-23 | Nuevolution A/S | Encoded molecules by translation (emt) |
| US7713923B2 (en) * | 2003-06-25 | 2010-05-11 | Massachusetts Institute Of Technology | Self-assembling peptides incorporating modifications and methods of use thereof |
| DK1636250T3 (en) | 2003-06-25 | 2016-02-22 | Massachusetts Inst Technology | SELF-ORGANIZING PEPTIDES, CONTAINING MODIFICATIONS, AND APPLICATIONS THEREOF |
| US7846891B2 (en) * | 2003-10-17 | 2010-12-07 | Massachusetts Institute Of Technology | Self-assembling peptides for regeneration and repair of neural tissue |
| US7704740B2 (en) | 2003-11-05 | 2010-04-27 | Michigan State University | Nanofibrillar structure and applications including cell and tissue culture |
| ES2380340T3 (es) * | 2003-12-05 | 2012-05-10 | Northwestern University | Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento |
| GB0413346D0 (en) | 2004-06-15 | 2004-07-21 | Theryte Ltd | Treating cancer |
| EP4023240A1 (en) | 2004-07-06 | 2022-07-06 | 3D Matrix, Inc. | Purified amphiphilic peptide compositions and uses thereof |
| US7884185B2 (en) * | 2004-07-28 | 2011-02-08 | University Of Delaware | Hydrogels and uses thereof |
| WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| US8039258B2 (en) | 2004-09-28 | 2011-10-18 | Ethicon, Inc. | Tissue-engineering scaffolds containing self-assembled-peptide hydrogels |
| US7399831B2 (en) * | 2004-10-25 | 2008-07-15 | The Brigham And Women's Hospital, Inc. | Targeted delivery of biological factors using self-assembling peptide nanofibers |
| US7429567B2 (en) * | 2005-01-04 | 2008-09-30 | The Brigham And Women's Hospital, Inc. | Sustained delivery of PDGF using self-assembling peptide nanofibers |
| US9162005B2 (en) | 2005-04-25 | 2015-10-20 | Arch Biosurgery, Inc. | Compositions for prevention of adhesions and other barrier applications |
| US9327010B2 (en) * | 2005-04-25 | 2016-05-03 | Massachusetts Institute Of Technology | Compositions and methods for promoting hemostasis and other physiological activities |
| US8420605B2 (en) | 2005-09-07 | 2013-04-16 | The University Of Strathclyde | Hydrogel compositions |
| CN101472620A (zh) | 2006-04-25 | 2009-07-01 | 麻省理工学院 | 用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法 |
| US20070287741A1 (en) * | 2006-06-13 | 2007-12-13 | Uri Herzberg | Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals |
| US8021570B2 (en) * | 2006-06-13 | 2011-09-20 | Wisconsin Alumni Research Foundation | β-peptide lyotropic liquid crystals and methods of manufacture and use thereof |
| DK2146733T3 (da) * | 2007-03-14 | 2021-01-11 | Arch Biosurgery Inc | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |
| EP2229960B1 (en) | 2007-12-05 | 2015-04-08 | 3-D Matrix, Ltd. | Wound healing/skin reconstruction material |
| EP2345433B1 (en) | 2008-10-06 | 2017-03-01 | 3-D Matrix, Ltd. | Tissue plug |
| US8512728B2 (en) | 2009-02-21 | 2013-08-20 | Sofradim Production | Method of forming a medical device on biological tissue |
| US20120085262A1 (en) | 2010-08-26 | 2012-04-12 | Freudenberg Forschungsdienste Kg | Production of Highly Concentrated Solutions of Self-Assembling Proteins |
| TW201315479A (zh) | 2011-10-12 | 2013-04-16 | Univ Nat Cheng Kung | 可促進動脈新生之醫藥組成物、及其製備方法與應用 |
| WO2014014613A2 (en) | 2012-06-20 | 2014-01-23 | President And Fellows Of Harvard College | Self-assembling peptides, peptide nanostructures and uses thereof |
| US9120841B2 (en) | 2012-09-28 | 2015-09-01 | Agency For Science, Technology And Research | Amphiphilic linear peptidepeptoid and hydrogel comprising the same |
| CN105658252A (zh) | 2013-08-22 | 2016-06-08 | 阿奇生物外科有限公司 | 用于控制流体移动的可植入网状物 |
-
2007
- 2007-04-25 US US11/740,284 patent/US9162005B2/en active Active
-
2008
- 2008-04-25 EP EP12196176.7A patent/EP2581097B1/en not_active Revoked
- 2008-04-25 HU HUE12196176A patent/HUE034194T2/en unknown
- 2008-04-25 JP JP2010506529A patent/JP5976272B2/ja not_active Expired - Fee Related
- 2008-04-25 PL PL12196176T patent/PL2581097T3/pl unknown
- 2008-04-25 CA CA2722465A patent/CA2722465C/en active Active
- 2008-04-25 EP EP08746940A patent/EP2150268A1/en not_active Ceased
- 2008-04-25 WO PCT/US2008/061622 patent/WO2008134544A1/en not_active Ceased
- 2008-04-25 DK DK12196176.7T patent/DK2581097T3/en active
- 2008-04-25 ES ES12196176.7T patent/ES2639625T3/es active Active
-
2015
- 2015-01-08 JP JP2015002075A patent/JP6113764B2/ja not_active Expired - Fee Related
- 2015-10-16 US US14/885,673 patent/US9789157B2/en active Active
-
2017
- 2017-03-14 JP JP2017048126A patent/JP6441978B2/ja not_active Expired - Fee Related
- 2017-09-26 US US15/716,262 patent/US10682386B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2150268A1 (en) | 2010-02-10 |
| CA2722465C (en) | 2017-10-31 |
| JP6441978B2 (ja) | 2018-12-19 |
| EP2581097A1 (en) | 2013-04-17 |
| US10682386B2 (en) | 2020-06-16 |
| WO2008134544A1 (en) | 2008-11-06 |
| US9789157B2 (en) | 2017-10-17 |
| US20080032934A1 (en) | 2008-02-07 |
| JP2015128593A (ja) | 2015-07-16 |
| DK2581097T3 (en) | 2017-08-07 |
| US20180008666A1 (en) | 2018-01-11 |
| US20160030505A1 (en) | 2016-02-04 |
| CA2722465A1 (en) | 2008-11-06 |
| JP2010526779A (ja) | 2010-08-05 |
| EP2581097B1 (en) | 2017-06-07 |
| HUE034194T2 (en) | 2018-02-28 |
| PL2581097T3 (pl) | 2017-11-30 |
| JP6113764B2 (ja) | 2017-04-12 |
| JP5976272B2 (ja) | 2016-08-23 |
| US9162005B2 (en) | 2015-10-20 |
| JP2017159044A (ja) | 2017-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2639625T3 (es) | Composiciones para prevenir adherencias y otras aplicaciones de barrera | |
| ES2756531T3 (es) | Mallas implantables para controlar el movimiento de fluidos | |
| ES2427565T3 (es) | Péptidos autoensambladores para promover la hemostasia | |
| CA2680824C (en) | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix | |
| CN105339020B (zh) | 预防胃肠梗阻的材料 | |
| AU2014308597A1 (en) | Implantable meshes for controlling the movement of fluids | |
| ES2305897T3 (es) | Proteccion de superficie de tejidos biologicos expuestos. | |
| ES2765630T3 (es) | Síntesis de nanoagregado de quitosano modificado mediante un péptido de autoensamblable y su aplicación para el transporte de proteínas | |
| ES2705602T3 (es) | Composiciones de péptidos anfifílicos purificadas y usos de las mismas | |
| HK1224959A1 (en) | Implantable meshes for controlling the movement of fluids | |
| HK1184397A (en) | Compositions for prevention of adhesions and other barrier applications | |
| HK1140431B (en) | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix | |
| HK1140431A (en) | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |